US Stock MarketDetailed Quotes
PYPD PolyPid
- 3.1000
- +0.1100+3.68%
Close Jan 10 16:00 ET
21.09MMarket Cap-0.12P/E (TTM)
3.1200High3.0065Low5.32KVolume3.1200Open2.9900Pre Close16.35KTurnover0.15%Turnover RatioLossP/E (Static)6.80MShares7.000052wk High9.78P/B11.16MFloat Cap2.370052wk Low--Dividend TTM3.60MShs Float583.5000Historical High--Div YieldTTM3.80%Amplitude2.3700Historical Low3.0750Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
PolyPid Stock Forum
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on w...
GlobeNewswire· 4 mins ago
630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
• Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track and Breakt...
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
Monday, 23rd December at 7:22 pm
• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
• Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track an...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based cli...
PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy
Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
No comment yet